JP2001508768A - イブプロフェンを含む水性飲料組成物 - Google Patents
イブプロフェンを含む水性飲料組成物Info
- Publication number
- JP2001508768A JP2001508768A JP52625398A JP52625398A JP2001508768A JP 2001508768 A JP2001508768 A JP 2001508768A JP 52625398 A JP52625398 A JP 52625398A JP 52625398 A JP52625398 A JP 52625398A JP 2001508768 A JP2001508768 A JP 2001508768A
- Authority
- JP
- Japan
- Prior art keywords
- ibuprofen
- composition
- aqueous
- active ingredient
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 組成物は水を添加して7未満のpHを有する水性調製品を得、そしてイブプ ロフェン薬剤と緊密に混合したリン脂質物質を含み、リン脂質物質は組成物に水 を添加すると実質的にイブプロフェン活性成分を含まない水性相および本質的に リン脂質物質およびイブプロフェン活性成分を含む不溶性薬理学的活性成分から 成る離散相を含む水性調製品を形成できることを特徴とする、水と混合して7未 満のpHを有する水性調製品を得る場合、100℃未満の融点を有するイブプロフ ェン活性成分を形成する、イブプロフェン薬剤を含む1種以上の薬剤を含むイブ プロフェン組成物。 2. イブプロフェン活性成分の融点以上の温度で水と組合せると、本質的にリ ン脂質物質およびイブプロフェン活性成分を含む不溶性薬理学的活性成分から成 る離散油相を有するエマルジョンの形成に適応する、請求項1記載の組成物。 3. 80〜100℃の範囲の温度で水と組合せると、本質的にリン脂質物質お よびイブプロフェン活性成分を含む不溶性薬理学的活性成分から成る離散油相を 有するエマルジョンの形成に適応する、請求項1または2記載の組成物。 4. イブプロフェン活性成分はイブプロフェンまたはS(+)−イブプロフェ ンを含む、請求項1から3のいずれか1項に記載の組成物。 5. イブプロフェン薬剤はラセミ体イブプロフェンまたはS(+)−イブプロ フェンである、請求項1から4のいずれか1項に記載の組成物。 6. リン脂質物質対イブプロフェン薬剤の比は0.02:1〜0.2〜1重量 部の範囲にある、請求項1から5のいずれか1項に記載の組成物。 7. リン脂質物質対イブプロフェン薬剤の比は0.03〜0.07重量部の範 囲にある、請求項6記載の組成物。 8. リン脂質物質は1種以上の天然レシチン物質を含む、請求項1から7のい ずれか1項に記載の組成物。 9. リン脂質物質は大豆レシチンを含む、請求項8に記載の組成物。 10. 酸性成分を含有する、請求項1から9のいずれか1項に記載の組成物。 11. 非リン脂質界面活性剤を含有する、請求項1から10のいずれか1項に 記載の組成物。 12. リン脂質対界面活性剤比は1:5〜5:1重量部の範囲にある、請求項 11記載の組成物。 13. 界面活性剤はラウリル硫酸ナトリウムを含む、請求項11または12記 載の組成物。 14. さらに糖成分を含むキャリアを含む、請求項1から13のいずれか1項 に記載の組成物。 15. 抗ヒスタミン、せきどめ、充血除去剤、去痰剤、筋肉弛緩剤、ビタミン 、カフェイン、および共−鎮痛薬またはその混合物を含むせきおよび/またはか ぜ治療に有用なそれ以上の薬剤を含む、請求項1から14のいずれか1項に記載 の組成物。 16. (a)100℃未満の融点を有するイブプロフェン活性成分および (b)水と組合せるとイブプロフェン活性成分を離散相に形成しうるリン脂質物 質、 を含む水性相および離散相を含む単位用量水性調製品であって、水性調製品は7 未満のpHを有し、その水性相は本質的にイブプロフェン活性成分を含まず、その 離散相は本質的にリン脂質物質およびイブプロフェン活性成分を含む不溶性薬理 学的活性成分から成ることを特徴とする上記水性調製品。 17. 水性相がイブプロフェン活性成分の融点以上の温度である場合、離散油 相は本質的にリン脂質物質および液体イブプロフェン活性成分から成る、請求項 16記載の水性調製品。 18. イブプロフェン活性成分はイブプロフェンまたはS(+)−イブプロフ ェンである、請求項17記載の水性調製品。 19. 水性相が抗ヒスタミン、咳どめ、充血除去剤、去痰剤、筋肉弛緩剤、カ フェイン、ビタミンおよび共−鎮痛薬またはその混合物を含むせきおよび/また はかぜ治療に有用なそれ以上の薬剤を含有する、請求項16から18のいずれか 1項に記載の水性調製品。 20. 離散相は本質的にリン脂質物質およびイブプロフェンから成る、請求項 16から19のいずれか1項に記載の水性調製品。 21. リン脂質は1種以上の天然に存在するレシチン物質を含む、請求項16 から20のいずれか1項に記載の水性調製品。 22. (a)水と組合せると7未満のpHを有する水性調製品を与え、100℃ 未満の融点を有するイブプロフェン活性成分を形成するイブプロフェン薬剤を含 む1種以上の薬剤、 (b)イブプロフェン組成物を水と組合せるとイブプロフェン活性成分を離散相 中に形成しうるリン脂質物質、および必要の場合、 (c)7未満のpHを有する水性調製品を得るのに適応した酸性成分、 の緊密混合物を含むイブプロフェン組成物を水と組合せる工程を特徴とし、水と イブプロフェン組成物の組合せにより7未満のpHを有する水性調製品を実質的に 直ちに形成し、離散相は本質的にリン脂質物質およびイブプロフェン活性成分を 含む不溶性薬理学的活性成分から成る、実質的にイブプロフェンを含まない水性 相およびイブプロフェンを添加した離散相を含む単位用量水性調製品の製造方法 。 23. イブプロフェン組成物と水をイブプロフェン活性成分の融点以上の温度 で組合わせることにより水性エマルジョンを製造する、請求項21記載の方法。 24. 離散相は本質的にイブプロフェンから成る、請求項22または23に記 載の方法。 25. (a)イブプロフェン薬剤と水を組合せると7未満のpHを有する水性調 製品を与え100℃未満の融点を有するイブプロフェン活性成分を形成するイブ プロフェン薬剤を含む1種以上の薬剤と、エマルジョンまたは分散体を含む水性 調製品を形成しうるリン脂質物質との緊密混合物を形成し、エマルジョンまたは 分散体の離散相は本質的にリン脂質物質およびイブプロフェン活性成分、任意に は他の補形剤を含む不溶性薬理学的活性成分から成り、および (b)混合物を単位用量組成物に処方する、ことを含む、0〜100℃の範囲 の温度で水を添加して実質的にイブプロフェンを含まない水性相および離散イブ プロフェン相を有する水性調製品を供するのに適応したイブプロフェン組成物の 製造方法。 26. 請求項16から21のいずれか1項に記載の単位用量水性調製品をその 必要とするヒトに投与することを含む抗炎症、鎮痛および/または下熱応答を得 る方法。 27. 炎症、痛みおよび/または発熱を治療する薬剤の製造に請求項16から 21のいずれか1項で特許請求した調製品の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9625589.8A GB9625589D0 (en) | 1996-12-10 | 1996-12-10 | Therapeutic agents |
GB9625589.8 | 1996-12-10 | ||
PCT/EP1997/007137 WO1998025595A2 (en) | 1996-12-10 | 1997-12-09 | Aqueous drink composition comprising ibuprofen |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001508768A true JP2001508768A (ja) | 2001-07-03 |
Family
ID=10804192
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52625398A Ceased JP2001508768A (ja) | 1996-12-10 | 1997-12-09 | イブプロフェンを含む水性飲料組成物 |
Country Status (27)
Country | Link |
---|---|
US (1) | US6287592B1 (ja) |
EP (1) | EP0946156B1 (ja) |
JP (1) | JP2001508768A (ja) |
KR (1) | KR20000069418A (ja) |
CN (1) | CN1275910A (ja) |
AR (1) | AR010758A1 (ja) |
AT (1) | ATE213628T1 (ja) |
AU (1) | AU723608B2 (ja) |
BG (1) | BG103552A (ja) |
CA (1) | CA2274773C (ja) |
CZ (1) | CZ204599A3 (ja) |
DE (1) | DE69710774T2 (ja) |
DK (1) | DK0946156T3 (ja) |
ES (1) | ES2173516T3 (ja) |
GB (1) | GB9625589D0 (ja) |
HK (1) | HK1021941A1 (ja) |
HU (1) | HUP0003583A2 (ja) |
IL (1) | IL130367A0 (ja) |
NO (1) | NO992806L (ja) |
NZ (1) | NZ336079A (ja) |
PL (1) | PL338920A1 (ja) |
PT (1) | PT946156E (ja) |
RU (1) | RU2207851C2 (ja) |
SK (1) | SK76799A3 (ja) |
TR (1) | TR199901250T2 (ja) |
WO (1) | WO1998025595A2 (ja) |
ZA (1) | ZA9711029B (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017522901A (ja) * | 2014-06-11 | 2017-08-17 | ポビバ ティー, エルエルシーPoviva Tea, Llc | 親油性活性剤を注入された飲食料品組成物とその使用方法 |
JP2020074791A (ja) * | 2014-06-11 | 2020-05-21 | ポビバ ティー, エルエルシーPoviva Tea, Llc | 親油性活性剤を注入された飲食料品組成物とその使用方法 |
US11311559B2 (en) | 2020-04-20 | 2022-04-26 | Poviva Corp. | Compositions and methods for enhanced delivery of antiviral agents |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040077604A1 (en) * | 2001-12-19 | 2004-04-22 | Lenard Lichtenberger | Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity |
EP1335732B1 (de) * | 2001-03-26 | 2004-05-12 | Giventis GmbH | Nahrungsmittel zur steigerung der kognitiven leistungsfähigkeit |
US20040132823A1 (en) * | 2001-11-02 | 2004-07-08 | Leo Pavliv | Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid |
US8598219B2 (en) | 2003-01-30 | 2013-12-03 | Helsinn Healthcare Sa | Liquid pharmaceutical formulations of palonosetron |
JO2735B1 (en) | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formations of balloonosterone |
TWI355936B (en) * | 2003-02-18 | 2012-01-11 | Helsinn Healthcare Sa | Uses of palonosetron hydrochloride |
WO2005051347A2 (en) * | 2003-10-30 | 2005-06-09 | Dianne Elizabeth Marshall | A simple process and formulation for making taste- masked ibuprofen liquid preparations and similar good-tasting preparation of other pharmaceutically active or bitter, poor tasting compounds for the production of liquid preparations |
US20050255154A1 (en) * | 2004-05-11 | 2005-11-17 | Lena Pereswetoff-Morath | Method and composition for treating rhinitis |
US20050266031A1 (en) * | 2004-05-25 | 2005-12-01 | Jay Dickerson | Pharmaceutical suspension composition |
KR100582604B1 (ko) | 2004-06-16 | 2006-05-23 | 보람제약주식회사 | 항산화제를 포함한 이부프로펜 및 덱시부프로펜의마이크로 에멀젼과 이를 이용한 투명 액제 및 투명연질캡슐 제제 |
DE102004043824A1 (de) * | 2004-09-10 | 2006-03-16 | Cognis Ip Management Gmbh | Emulsionen mit ungesättigten Fettsäuren und deren Estern |
US20060292225A1 (en) * | 2005-06-24 | 2006-12-28 | Felix Arthur M | Water soluble analgesic formulations and methods for production |
US20140072617A1 (en) * | 2007-09-26 | 2014-03-13 | Lvmh Recherche | Method for preventing or slowing down the appearance of the effects of skin ageing using a tocopheryl phosphate in liposomes |
US20110308985A1 (en) * | 2009-02-26 | 2011-12-22 | Gina Van Bogaert | Composition of a liposomal gel containing hydrocortisone, its metabolites, precursors or mixtures thereof and the use thereof |
GB2469849A (en) * | 2009-04-29 | 2010-11-03 | Perrigo | Unit dose sachets comprising Ibuprofen |
RU2532027C2 (ru) * | 2009-07-24 | 2014-10-27 | Мика Фарма Гезельшафт Фюр Ди Энтвиклюнг Унд Фермарктунг Фармацойтишер Продукте Мбх | Жидкие композиции, способные к пенообразованию и включающие активные средства, и способы их получения и разработки |
GB2477590A (en) | 2010-02-05 | 2011-08-10 | Biocopea Ltd | A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier |
US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US9737500B2 (en) | 2010-10-29 | 2017-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US20130309215A1 (en) * | 2012-05-15 | 2013-11-21 | Mika Pharma Gesellschaft Fur Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh | Pharmaceutical composition |
WO2015163832A1 (en) | 2014-04-25 | 2015-10-29 | Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. | An ibuprofen and famotidine combined composition having improved stability |
US10596117B1 (en) | 2014-12-31 | 2020-03-24 | Eric Morrison | Lipoleosomes as carriers for aromatic amide anesthetic compounds |
US10561627B2 (en) | 2014-12-31 | 2020-02-18 | Eric Morrison | Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films |
US11007161B1 (en) | 2014-12-31 | 2021-05-18 | Eric Morrison | Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS52111533A (en) | 1976-03-12 | 1977-09-19 | Kanebo Ltd | Preparation of fine powder of ibuprophene |
DE2914788A1 (de) * | 1979-04-11 | 1980-10-16 | Nattermann A & Cie | Parenteral applizierbare, stabile arzneimittelloesungen mit entzuendungshemmender wirkung |
JPS5859912A (ja) | 1981-10-06 | 1983-04-09 | Green Cross Corp:The | 鎮痛消炎物質脂肪乳剤 |
JPS5913720A (ja) | 1982-07-15 | 1984-01-24 | Green Cross Corp:The | フルルビプロフエン脂肪乳剤 |
JPS60208910A (ja) | 1984-03-31 | 1985-10-21 | Green Cross Corp:The | 水難溶性薬物・リン脂質複合体の製造方法 |
JPH0611697B2 (ja) | 1985-02-28 | 1994-02-16 | エスエス製薬株式会社 | 経口投与持続性カプセル剤 |
US4816247A (en) | 1985-09-11 | 1989-03-28 | American Cyanamid Company | Emulsion compositions for administration of sparingly water soluble ionizable hydrophobic drugs |
US4879108A (en) * | 1985-12-20 | 1989-11-07 | Warner-Lambert Company | Confectionery delivery system for antipyretics |
GB8623557D0 (en) | 1986-10-01 | 1986-11-05 | Boots Co Plc | Therapeutic agents |
GB8630273D0 (en) | 1986-12-18 | 1987-01-28 | Til Medical Ltd | Pharmaceutical delivery systems |
CA1319886C (en) | 1987-02-03 | 1993-07-06 | Alberto Ferro | Mixed micelle solutions |
US5288500A (en) * | 1987-03-13 | 1994-02-22 | Benzon Pharma A/S | Oral composition containing particles comprising an active substance |
IT1226549B (it) * | 1988-07-12 | 1991-01-24 | Resa Farma | Composizioni farmaceutiche ad attivita' analgesica ed antiinfiammatoria per uso orale, dotate di ottima palatabilita' ed esenti da effetti irritanti sulle mucose. |
US4975465A (en) | 1989-03-28 | 1990-12-04 | American Home Products Corporation | Orally administrable ibuprofen compositions |
JP2844756B2 (ja) | 1989-12-01 | 1999-01-06 | 日本新薬株式会社 | 脂肪乳剤 |
GB9007052D0 (en) | 1990-03-29 | 1990-05-30 | Skua Investments Ltd | Pharmaceutical formulations |
US5149655A (en) * | 1990-06-21 | 1992-09-22 | Agracetus, Inc. | Apparatus for genetic transformation |
US5110606A (en) * | 1990-11-13 | 1992-05-05 | Affinity Biotech, Inc. | Non-aqueous microemulsions for drug delivery |
GB9207990D0 (en) * | 1992-04-10 | 1992-05-27 | Smithkline Beecham Plc | Pharmaceutical composition |
WO1994005260A1 (en) | 1992-09-03 | 1994-03-17 | Affinity Biotech, Inc. | Taste-masking pharmaceutical compositions and methods for making the same |
GB9302720D0 (en) * | 1993-02-11 | 1993-03-24 | Scherer Ltd R P | Products in capsule form for use in aqueous solution |
CA2091152C (en) * | 1993-03-05 | 2005-05-03 | Kirsten Westesen | Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof |
US5785976A (en) * | 1993-03-05 | 1998-07-28 | Pharmacia & Upjohn Ab | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof |
CA2120197A1 (en) | 1993-04-02 | 1994-10-03 | Kenji Endo | Stable aqueous dispersions containing liposomes |
US5407921A (en) | 1993-07-01 | 1995-04-18 | Kao Corporation | Method for suppressing bitter taste |
DE4323636A1 (de) | 1993-07-15 | 1995-01-19 | Hoechst Ag | Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung |
ZA945944B (en) | 1993-08-13 | 1996-02-08 | Eurand America Inc | Procedure for encapsulating nsaids |
US5672358A (en) * | 1994-06-21 | 1997-09-30 | Ascent Pharmaceuticals, Inc. | Controlled release aqueous emulsion |
US5693337A (en) | 1994-07-13 | 1997-12-02 | Wakamoto Pharmaceutical Co., Ltd. | Stable lipid emulsion |
IT1270678B (it) | 1994-10-20 | 1997-05-07 | Bayer Ag | Liposomi al chetoprofen |
DE4440337A1 (de) * | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
TW442287B (en) * | 1995-06-13 | 2001-06-23 | American Home Produits Corp | Organoleptically acceptable oral pharmaceutical composition comprising the S(+)1,8-diethyl-1-1,3,4,9-tetrahydropyrano[3,4-b] indole-1-acetic acid (Etodolac) |
IT1276160B1 (it) | 1995-11-22 | 1997-10-27 | Recordati Chem Pharm | Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee |
US5891465A (en) | 1996-05-14 | 1999-04-06 | Biozone Laboratories, Inc. | Delivery of biologically active material in a liposomal formulation for administration into the mouth |
-
1996
- 1996-12-10 GB GBGB9625589.8A patent/GB9625589D0/en active Pending
-
1997
- 1997-12-09 KR KR1019997005194A patent/KR20000069418A/ko not_active Application Discontinuation
- 1997-12-09 DK DK97953861T patent/DK0946156T3/da active
- 1997-12-09 EP EP97953861A patent/EP0946156B1/en not_active Expired - Lifetime
- 1997-12-09 ZA ZA9711029A patent/ZA9711029B/xx unknown
- 1997-12-09 AT AT97953861T patent/ATE213628T1/de not_active IP Right Cessation
- 1997-12-09 JP JP52625398A patent/JP2001508768A/ja not_active Ceased
- 1997-12-09 ES ES97953861T patent/ES2173516T3/es not_active Expired - Lifetime
- 1997-12-09 CA CA002274773A patent/CA2274773C/en not_active Expired - Fee Related
- 1997-12-09 CZ CZ992045A patent/CZ204599A3/cs unknown
- 1997-12-09 SK SK767-99A patent/SK76799A3/sk unknown
- 1997-12-09 WO PCT/EP1997/007137 patent/WO1998025595A2/en not_active Application Discontinuation
- 1997-12-09 DE DE69710774T patent/DE69710774T2/de not_active Expired - Lifetime
- 1997-12-09 AU AU57605/98A patent/AU723608B2/en not_active Expired
- 1997-12-09 PT PT97953861T patent/PT946156E/pt unknown
- 1997-12-09 CN CN97181607A patent/CN1275910A/zh active Pending
- 1997-12-09 RU RU99114830/14A patent/RU2207851C2/ru not_active IP Right Cessation
- 1997-12-09 TR TR1999/01250T patent/TR199901250T2/xx unknown
- 1997-12-09 IL IL13036797A patent/IL130367A0/xx unknown
- 1997-12-09 US US09/319,242 patent/US6287592B1/en not_active Expired - Fee Related
- 1997-12-09 PL PL97338920A patent/PL338920A1/xx unknown
- 1997-12-09 HU HU0003583A patent/HUP0003583A2/hu unknown
- 1997-12-10 AR ARP970105797A patent/AR010758A1/es not_active Application Discontinuation
-
1999
- 1999-06-08 NZ NZ336079A patent/NZ336079A/en unknown
- 1999-06-09 NO NO992806A patent/NO992806L/no not_active Application Discontinuation
- 1999-07-05 BG BG103552A patent/BG103552A/xx unknown
-
2000
- 2000-02-17 HK HK00100956A patent/HK1021941A1/xx not_active IP Right Cessation
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017522901A (ja) * | 2014-06-11 | 2017-08-17 | ポビバ ティー, エルエルシーPoviva Tea, Llc | 親油性活性剤を注入された飲食料品組成物とその使用方法 |
CN107072278A (zh) * | 2014-06-11 | 2017-08-18 | 波维瓦茶业有限责任公司 | 加入亲脂性活性剂的食品和饮料组合物及其使用方法 |
US10374036B2 (en) | 2014-06-11 | 2019-08-06 | Poviva Tea, Llc | Food and beverage compositions infused with lipophilic active agents and methods of use thereof |
US10381440B2 (en) | 2014-06-11 | 2019-08-13 | Poviva Tea, Llc | Food and beverage compositions infused with lipophilic active agents and methods of use thereof |
JP2020074791A (ja) * | 2014-06-11 | 2020-05-21 | ポビバ ティー, エルエルシーPoviva Tea, Llc | 親油性活性剤を注入された飲食料品組成物とその使用方法 |
US11311559B2 (en) | 2020-04-20 | 2022-04-26 | Poviva Corp. | Compositions and methods for enhanced delivery of antiviral agents |
Also Published As
Publication number | Publication date |
---|---|
EP0946156A2 (en) | 1999-10-06 |
DE69710774T2 (de) | 2002-10-31 |
IL130367A0 (en) | 2000-06-01 |
NO992806L (no) | 1999-08-09 |
AR010758A1 (es) | 2000-07-12 |
CZ204599A3 (cs) | 1999-09-15 |
DE69710774D1 (de) | 2002-04-04 |
WO1998025595A3 (en) | 2000-05-04 |
HUP0003583A2 (hu) | 2001-04-28 |
HK1021941A1 (en) | 2000-07-21 |
ES2173516T3 (es) | 2002-10-16 |
ATE213628T1 (de) | 2002-03-15 |
EP0946156B1 (en) | 2002-02-27 |
AU723608B2 (en) | 2000-08-31 |
PL338920A1 (en) | 2000-11-20 |
PT946156E (pt) | 2002-08-30 |
AU5760598A (en) | 1998-07-03 |
GB9625589D0 (en) | 1997-01-29 |
TR199901250T2 (xx) | 2000-06-21 |
DK0946156T3 (da) | 2002-06-10 |
RU2207851C2 (ru) | 2003-07-10 |
CA2274773C (en) | 2008-08-26 |
SK76799A3 (en) | 2000-05-16 |
KR20000069418A (ko) | 2000-11-25 |
WO1998025595A2 (en) | 1998-06-18 |
CN1275910A (zh) | 2000-12-06 |
NZ336079A (en) | 2001-03-30 |
NO992806D0 (no) | 1999-06-09 |
ZA9711029B (en) | 1998-06-10 |
US6287592B1 (en) | 2001-09-11 |
CA2274773A1 (en) | 1998-06-18 |
BG103552A (en) | 2000-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2207851C2 (ru) | Терапевтические средства | |
US9381190B2 (en) | Melatonin tablet and methods of preparation and use | |
TW586943B (en) | Process for manufacturing bite-dispersion tablets | |
US10668013B2 (en) | Chewable gelled emulsions | |
JP2948317B2 (ja) | 噛める薬物投与用組成物 | |
JP2002510279A (ja) | 徐放性水性エマルション | |
EP3766480A1 (en) | Orally disintegrating tablet containing solid lipid particles and methods for their preparation and use | |
AU706027B2 (en) | Pharmaceutical composition for oral administration of flavonoids | |
US20030232097A1 (en) | Oily wax matrix suspension formulation comprising ibuprofen free acid and potassium salt of ibuprofen | |
MX2012008300A (es) | Formulaciones farmaceuticas de naproxeno para la encapsulacion en gel blando y combinaciones de las msmas. | |
JP2003525893A (ja) | 新規な自己乳化薬物送達系 | |
CN104640537A (zh) | 用于口服剂型的低熔点丙酸衍生物粒子 | |
JP2001509175A (ja) | 味覚的に口に合わない製剤用味隠蔽組成物 | |
MXPA99005310A (en) | Therapeutic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041102 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20060627 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080722 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081022 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081201 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081125 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090109 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081222 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090209 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20090303 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090526 |